For pricing in CAD please contact us.

Adenosine A2A Receptor (A2A)  - 10 µg

Adenosine A2A Receptor (A2A) - 10 µg

Regular price
$1,224.67 USD
Regular price
Sale price
$1,224.67 USD
Unit price
Sold out

Target name: Adenosine receptor (A2A receptor)

Catalogue number: PP1

Class: GPCR Class A

Sequence: Full-length, wildtype sequence, with a N-terminus Strep tag II, 8xHis-tag, and TEV protease cleavage site.

Affinity Tag​: His/Strep (both N-terminal)​

Origin: Human (Homo sapiens)​

Theor. MW: 47,7kDa

Accession #: P29274 (UniProt)​

Shipment temperature: Dry Ice

Storage conditions: Store at -80°C​


Expression system: Sf9 insect cells (baculovirus)​

Purity: >90%

Purification: Immobilized Metal Affinity Chromatography

Activity: Confirmed by radiobinding assay

Concentration​: Up to 5mg/ml

Sample buffer: 50mM Hepes pH 7.4, 200mM NaCl, 0.05%/0.006% DDM/CHS

Available quantity: From 10µg up to mg scale




Adenosine Receptors : CALIXAR's unique & custom-built approach

CALIXAR’s A2A Adenosine receptors facilitate reliable fragment-based drug design (FBDD), structure-based drug discovery (SBDD) and antibody discovery corresponding to this specific target. 

Unlike CALIXAR’s A2A Adenosine receptors, other alternative methods result in an adenosine receptor that becomes mutated and truncated (96 amino-acids truncation in the C-terminus). Additionally, this mutated version becomes locked within an antagonist conformation.


CALIXAR’s A2A Adenosine receptor is the first native full-length and functional target on the market. Other existing A2A targets are either mutated or truncated. Our A2A protein is produced in a eukaryotic system with the proper post-translational modifications (glycosylation).


CALIXAR’s A2A Adenosine receptors are high-quality membrane proteins used for (bio)drug discovery and are adapted for use in pharmaceutical, biotechnology companies, and as well as for academic teams that are involved in the life science fields.


  • Antibodies (including nanobodies, scaffold proteins, aptamers)
  • Small molecules
  • 3D Structures (classical X-ray or XFEL, Cryo-EM, NMR)
  • Drug discovery (Screening: HTS, FBDD, SBDD; Hit and lead validation)
  • Antibody discovery (Immunization and display technologies)
  • Clinical stage (drug validation on reliable native A2A)​

As with all GPCRs, the A2A Adenosine receptor is an unstable target and is difficult to produce natively with conventional approaches. Previously, A2A Adenosine receptors could only be locked in one specific conformation (e.g. antagonist) and were only ever prepared in a solution that inherently could not be pure, nor native (truncated, mutated) and without PTMs. A2A’s have only ever been inherently unstable, but not anymore.

Today, CALIXAR’s A2A receptors are able to bind to agonists, antagonists, as well as allosteric modulators (Igonet S. et al., 2018, Scientific Reports). Our A2A receptors also maintain their structural and functional integrity and are purified and stabilized to full length and wild-type (native) proteins.

Adenosine Receptor References


Enabling STD-NMR fragment screening using stabilized native GPCR : A case study of adenosine receptor

Igonet S et al. 2018


Towards Native and Stable GPCRs for Conformational Antibody Development

Jawhari A. Boston, 2015 


Novel systematic detergent screening method for membrane proteins solubilization.

Desuzinges Mandon E. et al. 2017